News & Blog

AVILAR THERAPEUTICS TO PRESENT PRECLINICAL DATA FOR MTAC (M6PR TARGETING CHIMERA) EXTRACELLULAR PROTEIN DEGRADER PLATFORM AT THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS ANNUAL MEETING

Aspen Neuroscience Announces First Patient Dosed in First-in-Human Phase 1/2a Clinical Trial of Autologous Neuronal Cell Replacement Therapy for Parkinson’s Disease

Nobias Therapeutics Joins NVIDIA Inception Program for Startups

Immunitas Therapeutics Presents Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting

Abundance of KLRB1+ (CD161) T cells in anti-PD1 non responders coupled with enhanced tumor cytotoxicity of anti-CD161 (IMT-009) with anti-PD1 makes it a rational target for combination with anti-PD-(L)1 immunotherapy

ProJenX Announces Removal of Partial Clinical Hold for Prosetin Program by FDA

Immunitas Therapeutics to Present Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting

ProJenX Receives European Authorization for First Study of Prosetin in People Living with ALS

Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead

2023 – A Year in Retrospect